Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Paclitaxel and Sorafenib|DRUG: Paclitaxel
Sponsor: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Collaborators: iOMEDICO AG